CKD Bio Corp. (KRX:063160)

CKD Bio Statistics

Total Valuation

CKD Bio has a market cap or net worth of KRW 109.72 billion.

Market Cap	109.72B
Enterprise Value	n/a

Important Dates

The last earnings date was Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

CKD Bio has 5.49 million shares outstanding.

Current Share Class	5.49M
Shares Outstanding	5.49M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.05%
Owned by Institutions (%)	n/a
Float	3.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.69
PB Ratio	0.83
P/TBV Ratio	0.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 1.21.

Current Ratio	1.56
Quick Ratio	0.65
Debt / Equity	1.21
Debt / EBITDA	n/a
Debt / FCF	-6.97
Interest Coverage	-5.49

Financial Efficiency

Return on equity (ROE) is -16.26% and return on invested capital (ROIC) is -5.54%.

Return on Equity (ROE)	-16.26%
Return on Assets (ROA)	-4.96%
Return on Invested Capital (ROIC)	-5.54%
Return on Capital Employed (ROCE)	-10.76%
Revenue Per Employee	308.16M
Profits Per Employee	-44.57M
Employee Count	519
Asset Turnover	0.51
Inventory Turnover	2.04

Taxes

Income Tax	-3.66B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.91% in the last 52 weeks. The beta is 0.69, so CKD Bio's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	-10.91%
50-Day Moving Average	20,998.00
200-Day Moving Average	22,364.20
Relative Strength Index (RSI)	30.57
Average Volume (20 Days)	13,580

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CKD Bio had revenue of KRW 159.93 billion and -23.13 billion in losses. Loss per share was -4,216.38.

Revenue	159.93B
Gross Profit	6.95B
Operating Income	-25.06B
Pretax Income	-26.79B
Net Income	-23.13B
EBITDA	-7.40B
EBIT	-25.06B
Loss Per Share	-4,216.38

Balance Sheet

The company has 12.35 billion in cash and 159.13 billion in debt, with a net cash position of -146.78 billion or -26,755.58 per share.

Cash & Cash Equivalents	12.35B
Total Debt	159.13B
Net Cash	-146.78B
Net Cash Per Share	-26,755.58
Equity (Book Value)	131.58B
Book Value Per Share	23,985.21
Working Capital	48.83B

Cash Flow

In the last 12 months, operating cash flow was -16.59 billion and capital expenditures -6.24 billion, giving a free cash flow of -22.83 billion.

Operating Cash Flow	-16.59B
Capital Expenditures	-6.24B
Free Cash Flow	-22.83B
FCF Per Share	-4,161.57

Margins

Gross margin is 4.35%, with operating and profit margins of -15.67% and -14.46%.

Gross Margin	4.35%
Operating Margin	-15.67%
Pretax Margin	-16.75%
Profit Margin	-14.46%
EBITDA Margin	-4.63%
EBIT Margin	-15.67%
FCF Margin	n/a

Dividends & Yields

CKD Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.02%
Shareholder Yield	0.02%
Earnings Yield	-21.08%
FCF Yield	-20.81%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 27, 2019. It was a forward split with a ratio of 1.05.

Last Split Date	Dec 27, 2019
Split Type	Forward
Split Ratio	1.05

Scores

CKD Bio has an Altman Z-Score of 1.23 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.23
Piotroski F-Score	1